Clinical trial
Randomized, Multicenter, Double-Blind, Placebo-Controlled, Rising Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
NCT02391259 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Multicenter, Double-Blind, Placebo-Controlled, Rising Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
- Lead sponsor
- Amgen
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- November 30, 2011
- Enrollment
- 57 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.
systemic lupus erythematosus